{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:24:57Z","timestamp":1794273897210,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071006"],"award-info":[{"award-number":["82071006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201185"],"award-info":[{"award-number":["82201185"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2020JJ4129"],"award-info":[{"award-number":["2020JJ4129"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thyroid-associated ophthalmopathy (TAO) is the most common autoimmune inflammatory diseases of the orbit. The CD40-CD40L pathway has been regarded as a potential molecular mechanism contributing to the development and progression of TAO, and RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising inhibitor of the CD40-CD40L signaling in TAO treatment. In this study, CD40Apt was confirmed to specifically recognize mouse CD40-positive ortibtal fibroblast. Mouse orbital fibroblasts were isolated from TAO mice model orbital tissues and validated. In TGF-\u03b2-induced orbital fibroblast activation model in vitro, CD40Apt administration inhibited TGF-\u03b2-induced cell viability, decreased TGF-\u03b2-induced \u03b1-SMA, Collagen I, Timp-1, and vimentin levels, and suppressed TGF-\u03b2-induced phosphorylation of Erk, p38, JNK, and NF-\u03baB. In TAO mice model in vivo, CD40Apt caused no significant differences to the body weight of mice; furthermore, CD40Apt improved the eyelid broadening, ameliorated inflammatory infiltration and the hyperplasia in orbital muscle and adipose tissues in model mice. Concerning orbital fibroblast activation, CD40Apt reduced the levels of CD40, collagen I, TGF-\u03b2, and \u03b1-SMA in orbital muscle and adipose tissues of model mice. Finally, CD40Apt administration significantly suppressed Erk, p38, JNK, and NF-\u03baB phosphorylation. In conclusion, CD40Apt, specifically binds to CD40 proteins in their natural state on the cell surface with high affinity, could suppress mouse orbital fibroblast activation, therefore improving TAO in mice model through the CD40 and downstream signaling pathways. CD40Apt represents a promising antagonist of the CD40-CD40L signaling for TAO treatment.<\/jats:p>","DOI":"10.1186\/s12967-023-04217-0","type":"journal-article","created":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T12:01:47Z","timestamp":1687089707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse"],"prefix":"10.1186","volume":"21","author":[{"given":"Yizhi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuokun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,18]]},"reference":[{"issue":"12","key":"4217_CR1","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ophtha.2011.06.003","volume":"118","author":"R Rajendram","year":"2011","unstructured":"Rajendram R, et al. Smoking and strabismus surgery in patients with thyroid eye disease. Ophthalmology. 2011;118(12):2493\u20137.","journal-title":"Ophthalmology"},{"issue":"1","key":"4217_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cxo.12472","volume":"100","author":"DL Weiler","year":"2017","unstructured":"Weiler DL. Thyroid eye disease: a review. Clin Exp Optom. 2017;100(1):20\u20135.","journal-title":"Clin Exp Optom"},{"issue":"9","key":"4217_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1089\/thy.2007.0407","volume":"18","author":"GM Lehmann","year":"2008","unstructured":"Lehmann GM, et al. Immune mechanisms in thyroid eye disease. Thyroid. 2008;18(9):959\u201365.","journal-title":"Thyroid"},{"issue":"3","key":"4217_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1210\/edrv-10-3-366","volume":"10","author":"TJ Smith","year":"1989","unstructured":"Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev. 1989;10(3):366\u201391.","journal-title":"Endocr Rev"},{"issue":"6","key":"4217_CR5","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy. Endocr Rev. 2003;24(6):802\u201335.","journal-title":"Endocr Rev"},{"issue":"3","key":"4217_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF03345272","volume":"27","author":"RA Ajjan","year":"2004","unstructured":"Ajjan RA, Weetman AP. New understanding of the role of cytokines in the pathogenesis of Graves\u2019 ophthalmopathy. J Endocrinol Invest. 2004;27(3):237\u201345.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"4217_CR7","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3892\/mmr.2016.5570","volume":"14","author":"H Li","year":"2016","unstructured":"Li H, et al. Celastrol inhibits IL-1beta-induced inflammation in orbital fibroblasts through the suppression of NF-kappaB activity. Mol Med Rep. 2016;14(3):2799\u2013806.","journal-title":"Mol Med Rep"},{"issue":"3\u20134","key":"4217_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/08820130600754960","volume":"35","author":"CJ Baglole","year":"2006","unstructured":"Baglole CJ, et al. More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest. 2006;35(3\u20134):297\u2013325.","journal-title":"Immunol Invest"},{"issue":"11","key":"4217_CR9","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1210\/en.2015-1399","volume":"156","author":"H Wang","year":"2015","unstructured":"Wang H, et al. Pentraxin-3 is a TSH-inducible protein in human fibrocytes and orbital fibroblasts. Endocrinology. 2015;156(11):4336\u201344.","journal-title":"Endocrinology"},{"issue":"12","key":"4217_CR10","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1016\/j.ajpath.2016.08.017","volume":"186","author":"CF Woeller","year":"2016","unstructured":"Woeller CF, et al. The aryl hydrocarbon receptor and its ligands inhibit myofibroblast formation and activation: implications for thyroid eye disease. Am J Pathol. 2016;186(12):3189\u2013202.","journal-title":"Am J Pathol"},{"issue":"3","key":"4217_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/105072502753600133","volume":"12","author":"TJ Smith","year":"2002","unstructured":"Smith TJ. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2002;12(3):197\u2013203.","journal-title":"Thyroid"},{"issue":"8","key":"4217_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/bjophthalmol-2012-301537","volume":"96","author":"JS Yoon","year":"2012","unstructured":"Yoon JS, et al. Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves\u2019 orbitopathy. Br J Ophthalmol. 2012;96(8):1117\u201321.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"4217_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/JOE-12-0257","volume":"216","author":"JS Yoon","year":"2012","unstructured":"Yoon JS, et al. Cigarette smoke extract-induced adipogenesis in Graves\u2019 orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress. J Endocrinol. 2012;216(2):145.","journal-title":"J Endocrinol"},{"issue":"5","key":"4217_CR14","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1167\/iovs.08-2328","volume":"50","author":"CJ Hwang","year":"2009","unstructured":"Hwang CJ, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci. 2009;50(5):2262\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"4217_CR15","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1167\/iovs.05-0605","volume":"46","author":"SE Feldon","year":"2005","unstructured":"Feldon SE, et al. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves\u2019 ophthalmopathy. Invest Ophthalmol Vis Sci. 2005;46(11):3913\u201321.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"4217_CR16","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.1167\/iovs.12-9861","volume":"53","author":"EF Gillespie","year":"2012","unstructured":"Gillespie EF, et al. Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-kappaB. Invest Ophthalmol Vis Sci. 2012;53(12):7746\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6287","key":"4217_CR17","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/346818a0","volume":"346","author":"AD Ellington","year":"1990","unstructured":"Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346(6287):818\u201322.","journal-title":"Nature"},{"issue":"4968","key":"4217_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.2200121","volume":"249","author":"C Tuerk","year":"1990","unstructured":"Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505\u201310.","journal-title":"Science"},{"issue":"5454","key":"4217_CR19","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1126\/science.287.5454.820","volume":"287","author":"T Hermann","year":"2000","unstructured":"Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science. 2000;287(5454):820\u20135.","journal-title":"Science"},{"issue":"7552","key":"4217_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/521274a","volume":"521","author":"M Baker","year":"2015","unstructured":"Baker M. Reproducibility crisis: blame it on the antibodies. Nature. 2015;521(7552):274\u20136.","journal-title":"Nature"},{"issue":"10","key":"4217_CR21","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/mt.2011.145","volume":"19","author":"F Pastor","year":"2011","unstructured":"Pastor F, et al. Targeting 4\u20131BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther. 2011;19(10):1878\u201386.","journal-title":"Mol Ther"},{"issue":"10","key":"4217_CR22","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.1990","volume":"15","author":"S Oney","year":"2009","unstructured":"Oney S, et al. Development of universal antidotes to control aptamer activity. Nat Med. 2009;15(10):1224\u20138.","journal-title":"Nat Med"},{"key":"4217_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.biomaterials.2015.07.020","volume":"67","author":"MM Soldevilla","year":"2015","unstructured":"Soldevilla MM, et al. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. Biomaterials. 2015;67:274\u201385.","journal-title":"Biomaterials"},{"issue":"12","key":"4217_CR24","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1172\/JCI200317069","volume":"111","author":"CR Chen","year":"2003","unstructured":"Chen CR, et al. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest. 2003;111(12):1897\u2013904.","journal-title":"J Clin Invest"},{"issue":"3","key":"4217_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2249.2004.02641.x","volume":"138","author":"Y Nagayama","year":"2004","unstructured":"Nagayama Y, et al. TSH receptor-adenovirus-induced Graves\u2019 hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1\/Th2 paradigm. Clin Exp Immunol. 2004;138(3):417\u201322.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"4217_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1525-1578(10)60652-6","volume":"3","author":"J Meijerink","year":"2001","unstructured":"Meijerink J, et al. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn. 2001;3(2):55\u201361.","journal-title":"J Mol Diagn"},{"issue":"2","key":"4217_CR27","first-page":"129","volume":"49","author":"GA Bishop","year":"2001","unstructured":"Bishop GA, Hostager BS. Molecular mechanisms of CD40 signaling. Arch Immunol Ther Exp (Warsz). 2001;49(2):129\u201337.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"4217_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.0105-2896.2009.00862.x","volume":"233","author":"LA Criswell","year":"2010","unstructured":"Criswell LA. Gene discovery in rheumatoid arthritis highlights the CD40\/NF-kappaB signaling pathway in disease pathogenesis. Immunol Rev. 2010;233(1):55\u201361.","journal-title":"Immunol Rev"},{"issue":"5","key":"4217_CR29","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1167\/iovs.16-20684","volume":"58","author":"J Ko","year":"2017","unstructured":"Ko J, et al. Sphingosine-1-phosphate mediates fibrosis in orbital fibroblasts in Graves\u2019 orbitopathy. Invest Ophthalmol Vis Sci. 2017;58(5):2544\u201353.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"4217_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12016-016-8562-7","volume":"52","author":"M Ungerer","year":"2017","unstructured":"Ungerer M, et al. Review of mouse models of Graves\u2019 disease and orbitopathy-novel treatment by induction of tolerance. Clin Rev Allergy Immunol. 2017;52(2):182\u201393.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"4217_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1210\/er.2004-0023","volume":"26","author":"SM McLachlan","year":"2005","unstructured":"McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves\u2019 hyperthyroidism from animal models. Endocr Rev. 2005;26(6):800\u201332.","journal-title":"Endocr Rev"},{"issue":"6","key":"4217_CR32","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.4049\/jimmunol.168.6.2789","volume":"168","author":"Y Nagayama","year":"2002","unstructured":"Nagayama Y, et al. A novel murine model of Graves\u2019 hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol. 2002;168(6):2789\u201394.","journal-title":"J Immunol"},{"issue":"10","key":"4217_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1089\/thy.2007.0161","volume":"17","author":"Y Nagayama","year":"2007","unstructured":"Nagayama Y. Graves\u2019 animal models of Graves\u2019 hyperthyroidism. Thyroid. 2007;17(10):981\u20138.","journal-title":"Thyroid"},{"issue":"4","key":"4217_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/en.2014-1813","volume":"156","author":"HP Holthoff","year":"2015","unstructured":"Holthoff HP, et al. Prolonged TSH receptor A subunit immunization of female mice leads to a long-term model of Graves\u2019 disease, tachycardia, and cardiac hypertrophy. Endocrinology. 2015;156(4):1577\u201389.","journal-title":"Endocrinology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04217-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04217-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T12:01:51Z","timestamp":1687089711000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04217-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4217"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04217-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,18]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out in compliance with the principles and methods stated in the Guideline for the Care and Use of Laboratory Animals in the Third Xiangya Hospital. This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"396"}}